Is Roche's pRED fi­nal­ly ready to step out from be­hind Genen­tech for its close­up? Prob­a­bly not

John Reed
Bioreg­num
The view from John Car­roll

It’s been close to 5 years since John Reed jumped from San­ford-Burn­ham to be­come the head of Roche’s Basel-based pRED or­ga­ni­za­tion. And on­ly now is the big drug re­search group he leads get­ting a close­up af­ter years spent watch­ing his col­leagues at gRED — Genen­tech — steal the show with a string of block­buster hits.

The old pRED was shred­ded when Roche an­nounced in the sum­mer of 2012 that it would shut­ter its big R&D cam­pus in Nut­ley, NJ and move a group of sur­vivors in­to Man­hat­tan. The re­or­ga­ni­za­tion, like any such R&D or­ga­ni­za­tion, Reed told me in 2013, was pure “poi­son” for the group, vow­ing to stick with a re­search strat­e­gy and avoid any more such trau­mat­ic dis­rup­tions.

There was one key suc­cess, with Gazy­va, but that hasn’t per­formed spec­tac­u­lar­ly well so far on the mar­ket­ing side of things. And some of the drugs that Reed men­tioned to me back in 2013 — like RG7116 and emac­tuzum­ab — ap­pear to have ei­ther been lost along the way or still face a long clin­i­cal path. And even in­side Roche there ap­pears to have been some grow­ing frus­tra­tions.

Sev­erin Schwan

Roche CEO Sev­erin Schwan, though, is now ready to em­brace the long over­shad­owed pRED, tap­ping some mid-stage pro­grams as top prospects. Here’s what he had to tell Reuters:

“In pRED, some ex­cit­ing op­por­tu­ni­ties are now com­ing through af­ter a time when many things did not work. It goes in waves. You can’t pro­gram to have a cer­tain num­ber of mol­e­cules com­ing through the pipeline every year in each unit.”

An­oth­er ex­ec put it this way: “Thank God. It took a while, but pRED is fi­nal­ly start­ing to de­liv­er.”

So what’s in the spot­light?

A bis­pe­cif­ic called CEA-TCB that en­gages T cells for an at­tack on can­cer cells, a fol­low-up drug for Lu­cen­tis, ida­sunut­lin for AML and an autism drug.

It’s un­usu­al for any gi­ant phar­ma com­pa­ny like Roche to tout mid-stage pro­grams, which have a high mor­tal­i­ty rate, es­pe­cial­ly as mar­ket­ing chal­lenges can now just as eas­i­ly kill off a pro­gram just as sure­ly as bad da­ta ever could. But then it’s al­so ex­tra­or­di­nar­i­ly un­usu­al for a com­pa­ny like Roche to suc­cess­ful­ly ac­quire Genen­tech with­out killing the in­no­v­a­tive spir­it that drove a leg­endary string of new can­cer drugs in­to ex­is­tence.

The gen­er­al con­sen­sus at the time was that the but­toned down Basel crew would de­stroy the col­or­ful cul­ture at Genen­tech, elim­i­nat­ing its abil­i­ty to stay on the cut­ting edge of drug re­search. In­stead, even as top ex­ecs moved on to oth­er things, flow­er­ing Bay Area star­tups, the Bay Area com­pa­ny con­tin­ued to thrive.

Reed and pRED, both of which have main­tained a very low pro­file in re­cent years, still have a long way to go be­fore prov­ing whether Roche can cre­ate the same spir­it in the large­ly Eu­ro­pean or­ga­ni­za­tion.

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.